Somatostatin inhibits neutrophil elastase release in vitro.
The influence of the long-acting somatostatin analogue, SMS 201-995, on FMLP-induced neutrophil elastase release in vitro has been investigated. Doses from 150 ng/ml upwards inhibited elastase release, with 100% inhibition by 2500 ng/ml. Inhibition was demonstrated both by an assay measuring elastase immunometrically and by an assay based on its enzyme activity. The demonstration that SMS 201-995 inhibits protease release from polymorphonuclear leukocytes may have implications for the long-term clinical use of this somatostatin analogue.
Adeyemi
E O
EO
Department of Medicine, Royla Postgraduate Medical School, Hammersmith Hospital, London.
Savage
A P
AP
Bloom
S R
SR
Hodgson
H J
HJ
D000595:Amino Acid Sequence; D005260:Female; D006801:Humans; D015592:Immunoradiometric Assay; D066298:In Vitro Techniques; D007457:Iodine Radioisotopes; D008297:Male; D008969:Molecular Sequence Data; D009504:Neutrophils / Q000201:enzymology*; D015282:Octreotide / Q000494:pharmacology*; D010196:Pancreatic Elastase / Q000097:blood* / Q000378:metabolism; D013205:Staphylococcal Protein A
D007457:Iodine Radioisotopes; D013205:Staphylococcal Protein A; D010196:Pancreatic Elastase; D015282:Octreotide